Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/01.ane.0000260353.11142.d4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Hospital Dermatology: Review of Research in 2023-2024.
Cutis
November 2024
Dr. Wei is from the Department of Dermatology, University of Washington, Seattle. Dr. Micheletti is from the Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Inpatient consultative dermatologists play a critical role in the care of hospitalized patients with skin disease. Our review of the 2023-2024 dermatology literature identified several areas of active investigation relevant to inpatient dermatology. In this article, we highlight advances in the understanding of severe cutaneous adverse drug reactions, diagnosis and prevention of skin and soft tissue infections, and management of autoimmune blistering diseases (AIBDs).
View Article and Find Full Text PDFWhat's Eating You? Hookworm and Cutaneous Larva Migrans.
Cutis
November 2024
Dr. Bloomquist is from the School of Medicine, University of South Carolina, Columbia. Dr. Elston is from the Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston.
Hookworm infection represents a major global disease burden, in terms of both morbidity and economic impact, and there has been a resurgence of hookworms in developed nations where these parasites were once thought to be eradicated. Hookworms can infest humans or other mammals as their primary hosts depending on the species. The 2 most common species that seek human hosts-Necator americanus and Ancylostoma duodenale-enter the body through the epidermis, and hookworm infection may manifest as a pruritic and papular inflammatory reaction know as ground itch.
View Article and Find Full Text PDFFalse-Negative Review from the Mammography Audit: Refining Breast Imaging Practice.
Radiographics
February 2025
From the Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S Kingshighway Blvd, St. Louis, MO 63110.
Annual review of false-negative (FN) mammograms is a mandatory and critical component of the Mammography Quality Standards Act (MQSA) annual mammography audit. FN review can help hone reading skills and improve the ability to detect cancers at mammography. Subtle architectural distortion, asymmetries (seen only on one view), small lesions, lesions with probably benign appearance (circumscribed regular borders), isolated microcalcifications, and skin thickening are the most common mammographic findings when the malignancy is visible at retrospective review of FN mammograms.
View Article and Find Full Text PDFSafety of 1 mcg/mL as the starting dose in cluster protocol for hymenoptera immunotherapy.
Allergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!